Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF). VEGF is a chemical signal that stimulates the growth of new blood vessels (angiogenesis). Blood vessels grow uncontrollably in cancer, retinal proliferation of diabetes in the eye, and other diseases. Bevacizumab can block VEGF from creating new blood vessels. Bevacizumab was the first clinically available angiogenesis inhibitor in the Unite… (More on Avastin)